National Institute on Drug Abuse; Notice of Meeting, 50340-50341 [2022-17613]

Download as PDF 50340 Federal Register / Vol. 87, No. 157 / Tuesday, August 16, 2022 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Proposed Collection; 60-Day Comment Request; a Generic Submission for Formative Research, Pretesting and Customer Satisfaction of NCI’s Communication and Education Resources (NCI) AGENCY: National Institutes of Health, HHS. ACTION: Notice. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institutes of Health, National Cancer Institute (NCI) will publish periodic summaries of propose projects to be submitted to the Office of Management and Budget (OMB) for review and approval. DATES: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. SUMMARY: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Ilene France, Branch Chief, Office of Communication and Public Liaison, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD 20850 or call non-toll-free number (240) 276–7787 or Email your request, FOR FURTHER INFORMATION CONTACT: NCI’s Communication and Education Resources (NCI) for three years. As part of NCI’s mandate from Congress to disseminate information on cancer research, detection, prevention, and treatment, the Institute develops a wide variety of messages and materials. Testing these messages and materials assesses their potential effectiveness in reaching and communicating with their intended audience while they are still in the developmental stage and can be revised. The formative research and pretesting process thus contributes to maximizing NCI’s limited dollar resources for information dissemination and education. NCI also must ensure the relevance, utility, and appropriateness of the many educational programs and products that the Institute produces. Customer satisfaction studies help NCI identify modifications necessary to meet the needs of NCI’s various target audiences. Since the previous submission, there have been 6 approved sub-studies with an approved request of 13,473 burden hours over 2.5 years. Approval is requested for the conduct of multiple studies annually using such methods as interviews, focus groups, and various types of surveys. The content, timing, and number of respondents to be included in each substudy will vary, depending on the nature of the message/material/program being assessed, the methodology selected, and the target audiences. OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 13,500. including your address to: nciocpl@ mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing. SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires: written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimizes the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Proposed Collection Title: A Generic Submission for Formative Research, Pretesting and Customer Satisfaction of NCI’s Communication and Education Resources (NCI), 0925–0046, Expiration Date 11/30/2022, EXTENSION, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: This information collection request is to approve the Generic Submission for Formative Research, Pretesting and Customer Satisfaction of ESTIMATED ANNUALIZED BURDEN HOURS Form name Focus Groups, Individual In-Depth Interviews, Brief Interviews, Surveys, Website Usability Testing. Focus Groups, Individual In-Depth Interviews, Brief Interviews, Surveys, Website Usability Testing. Totals ............................................................. lotter on DSK11XQN23PROD with NOTICES1 Number of respondents Type of respondents Dated: August 10, 2022. Diane Kreinbrink, Project Clearance Liaison, National Cancer Institute, National Institutes of Health. [FR Doc. 2022–17518 Filed 8–15–22; 8:45 am] BILLING CODE 4140–01–P 18:35 Aug 15, 2022 Jkt 256001 Average time per response (in hours) Total annual burden hours Individuals (General Public). 9,000 1 45/60 6,750 Individuals (Health Care Professionals). 9,000 1 45/60 6,750 ....................................... ........................ 18,000 ........................ 13,500 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as VerDate Sep<11>2014 Number of responses per respondent PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 amended, notice is hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be held as a virtual meeting and is open to the public, as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed E:\FR\FM\16AUN1.SGM 16AUN1 Federal Register / Vol. 87, No. 157 / Tuesday, August 16, 2022 / Notices below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https:// videocast.nih.gov/). A portion of this meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. lotter on DSK11XQN23PROD with NOTICES1 Name of Committee: National Advisory Council on Drug Abuse. Date: September 13, 2022. Closed: 11:00 a.m. to 12:15 p.m. Agenda: To review and evaluate grant applications. Open: 12:45 p.m. to 5:00 p.m. Agenda: Presentations and other business of the Council. Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of Extramural Research, Office of the Director, National Institute on Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown Street, Bethesda, MD 20852, 301–443–6480, sweiss@ nida.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to Gillian Acca at gillian.acca@ nih.gov. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: www.drugabuse.gov/NACDA/ NACDAHome.html, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: August 11, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases, Special Emphasis Panel; Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections and Emerging Infectious Diseases; Research Area 002—Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infect. Date: September 2, 2022. Time: 10:00 a.m. to 2:30 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room E370, Rockville, MD 20892 (Virtual Meeting). Contact Person: Mohammed S. Aiyegbo, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E70, Rockville, MD 20852, (301) 761–7106, mohammed.aiyegbo@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: August 11, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–17614 Filed 8–15–22; 8:45 am] BILLING CODE 4140–01–P [FR Doc. 2022–17613 Filed 8–15–22; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 18:35 Aug 15, 2022 Jkt 256001 50341 PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Child Health and Human Development Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Child Health and Human Development Council. Date: September 12–13, 2022. Open Session: September 12, 2022, 12 p.m. to 5:00 p.m. Agenda: Opening Remarks, Administrative Matters, NICHD Directors’ Report, Annual DIR Report, and other business of Council. Place: Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Bethesda, MD 20892 (Video Assisted Meeting). Closed Session: September 13, 2022, 12 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Bethesda, MD 20892 (Video Assisted Meeting). Contact Person: Ms. Lisa Neal, Committee Management Officer, Committee Management Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6701B Rockledge Drive, Room 2208, Bethesda, MD 20892, (301) 204–1830, lisa.neal@nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when E:\FR\FM\16AUN1.SGM 16AUN1

Agencies

[Federal Register Volume 87, Number 157 (Tuesday, August 16, 2022)]
[Notices]
[Pages 50340-50341]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-17613]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Advisory 
Council on Drug Abuse.
    The meeting will be held as a virtual meeting and is open to the 
public, as indicated below. Individuals who plan to view the virtual 
meeting and need special assistance or other reasonable accommodations 
to view the meeting, should notify the Contact Person listed

[[Page 50341]]

below in advance of the meeting. The open session will be videocast and 
can be accessed from the NIH Videocasting and Podcasting website 
(https://videocast.nih.gov/).
    A portion of this meeting will be closed to the public in 
accordance with the provisions set forth in sections 552b(c)(4) and 
552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.

    Name of Committee: National Advisory Council on Drug Abuse.
    Date: September 13, 2022.
    Closed: 11:00 a.m. to 12:15 p.m.
    Agenda: To review and evaluate grant applications.
    Open: 12:45 p.m. to 5:00 p.m.
    Agenda: Presentations and other business of the Council.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of 
Extramural Research, Office of the Director, National Institute on 
Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown 
Street, Bethesda, MD 20852, 301-443-6480, [email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to Gillian Acca at 
[email protected]. The statement should include the name, 
address, telephone number and when applicable, the business or 
professional affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and 
any additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: August 11, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-17613 Filed 8-15-22; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.